Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 20/20 | 0.74 |
| ▸ | CDK1 | P06493 | 7/20 | 0.64 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.55 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.55 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.55 |
| ▸ | AXL | P30530 | 1/20 | 0.55 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.55 |
| ▸ | MERTK | Q12866 | 1/20 | 0.55 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.55 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.55 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.55 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.55 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.55 |
| ▸ | BRSK2 | Q8IWQ3 | 1/20 | 0.55 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.55 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.55 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17581337 | 1.00 | MAPKAPK2 (0.74) | MAPKAPK2CDK1RIPK2CCNB2ABCB11 | |
| SCHEMBL17581191 | 0.94 | MAPKAPK2 (0.73) | MAPKAPK2CDK1RIPK2CCNB2ABCB11 | |
| SCHEMBL23001622 | 0.91 | MAPKAPK2 (0.71) | MAPKAPK2CDK1RIPK2CCNB2ABCB11 | |
| SCHEMBL17581142 | 0.91 | MAPKAPK2 (0.71) | MAPKAPK2CDK1RIPK2CCNB2ABCB11 | |
| SCHEMBL17588989 | 0.91 | MAPKAPK2 (0.82) | MAPKAPK2CDK1RIPK2CCNB2ABCB11 | |
| SCHEMBL30242207 | 0.91 | MAPKAPK2 (0.82) | MAPKAPK2CDK1RIPK2CCNB2ABCB11 | |
| SCHEMBL17581289 | 0.89 | MAPKAPK2 (0.67) | MAPKAPK2CDK1RIPK2CCNB2ABCB11 | |
| SCHEMBL17581167 | 0.89 | MAPKAPK2 (0.83) | MAPKAPK2CDK1RIPK2CCNB2ABCB11 | |
| SCHEMBL17581294 | 0.88 | MAPKAPK2 (0.63) | MAPKAPK2CDK1RIPK2CCNB2ABCB11 | |
| SCHEMBL17581200 | 0.88 | MAPKAPK2 (0.70) | MAPKAPK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584757-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2023-02-21 | — | — | US | disclosed |
| US-11584757-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2023-02-21 | — | — | US | disclosed |
| EP-3912981-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-11-24 | — | — | EP | disclosed |
| EP-3912981-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-11-24 | — | — | EP | disclosed |
| EP-3193611-B1 | MK2 INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-03-24 | — | — | EP | disclosed |
| EP-3193611-B1 | MK2 INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-03-24 | — | — | EP | disclosed |
| US-20210053984-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2021-02-25 | — | — | US | disclosed |
| US-20210053984-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2021-02-25 | — | — | US | disclosed |
| US-10577380-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2020-03-03 | — | — | US | disclosed |
| US-10577380-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2020-03-03 | — | — | US | disclosed |
| US-9790235-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-10-17 | — | — | US | disclosed |
| US-20170114073-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-27 | — | — | US | disclosed |
| US-20170114073-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-27 | — | — | US | disclosed |
| US-20170114073-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-27 | — | — | US | disclosed |
| US-9458175-B2 | MK2 inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458175-B2 | MK2 inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458175-B2 | MK2 inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| WO-2016044463-A2 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160075720-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-03-17 | — | — | US | disclosed |
| US-20160075720-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577380-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | MAPKAPK2 7/4885CDK1 114/4885RIPK2 398/4885 |
| US-20170114073-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | MAPKAPK2 7/4885CDK1 114/4885RIPK2 398/4885 |
| US-20160075720-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | MAPKAPK2 7/4885CDK1 114/4885RIPK2 398/4885 |
| US-11584757-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | MAPKAPK2 7/4885CDK1 114/4885RIPK2 398/4885 |
| US-20210053984-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | MAPKAPK2 7/4885CDK1 114/4885RIPK2 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.